This is in keeping with other reported research.3,14,15,25,26,27 Studies by Hashim et al. conducted in a Malaysian population in 2020 and O’Flaherty et al. published in 2013 from the United Kingdom, both using Roche PTH assays, found that third-generation assays were lower by 30% and 40% compared to second-generation assays, respectively.28,29 In contrast, in the non-CKD group with eGFR above 60 mL/min/1.73 m2, the observed bias was 5.7%. The gene discussed is PTH; the disease is chronic kidney disease.